Free Trial
NYSEAMERICAN:MTNB

Matinas BioPharma (MTNB) Stock Price, News & Analysis

Matinas BioPharma logo
$0.62
-1.31 (-67.88%)
(As of 10/31/2024 ET)

About Matinas BioPharma Stock (NYSEAMERICAN:MTNB)

Key Stats

Today's Range
$0.54
$0.98
50-Day Range
N/A
52-Week Range
$0.54
$21.50
Volume
3.04 million shs
Average Volume
45,152 shs
Market Capitalization
$3.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It also offers MAT2501, an orally administered formulation of amikacin to treat chronic and acute bacterial infections, as well as non-tuberculosis mycobacterium. The company has strategic collaborations with the National Institute of Allergy and Infectious Diseases for the development of oral formulations of Gilead's remdesivir; BioNTech SE to evaluate the combination of mRNA formats with the LNC platform; and Genentech Inc. to develop oral formulations. Matinas BioPharma Holdings, Inc. was incorporated in 2013 and is based in Bedminster, New Jersey.

Matinas BioPharma Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
4th Percentile Overall Score

MTNB MarketRank™: 

Matinas BioPharma scored higher than 4% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Matinas BioPharma is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Matinas BioPharma is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Matinas BioPharma has a P/B Ratio of 0.14. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    1.64% of the float of Matinas BioPharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Matinas BioPharma has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Matinas BioPharma has recently increased by 28.23%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Matinas BioPharma does not currently pay a dividend.

  • Dividend Growth

    Matinas BioPharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.64% of the float of Matinas BioPharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Matinas BioPharma has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Matinas BioPharma has recently increased by 28.23%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Matinas BioPharma has a news sentiment score of -0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Matinas BioPharma this week, compared to 1 article on an average week.
  • Search Interest

    Only 2 people have searched for MTNB on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Matinas BioPharma to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Matinas BioPharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 9.60% of the stock of Matinas BioPharma is held by insiders.

  • Percentage Held by Institutions

    Only 11.77% of the stock of Matinas BioPharma is held by institutions.

  • Read more about Matinas BioPharma's insider trading history.
Receive MTNB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Matinas BioPharma and its competitors with MarketBeat's FREE daily newsletter.

MTNB Stock News Headlines

Matinas BioPharma says MAT2203 partnership negotiations terminated
Banking failure dead ahead
If you missed it, my emergency election broadcast is now available - but will be removed soon
Matinas BioPharma enacts reverse stock split
Matinas BioPharma Holdings Inc (6LJ.DU)
See More Headlines

MTNB Stock Analysis - Frequently Asked Questions

Matinas BioPharma's stock was trading at $0.2801 at the start of the year. Since then, MTNB stock has increased by 121.3% and is now trading at $0.62.
View the best growth stocks for 2024 here
.

Matinas BioPharma Holdings, Inc. (NYSEAMERICAN:MTNB) released its quarterly earnings data on Wednesday, August, 14th. The company reported ($0.02) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.02).

Shares of MTNB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Matinas BioPharma investors own include Acasti Pharma (ACST), SCYNEXIS (SCYX), Tesla (TSLA), Corbus Pharmaceuticals (CRBP), Viking Therapeutics (VKTX), Sorrento Therapeutics (SRNE) and TherapeuticsMD (TXMD).

Company Calendar

Last Earnings
8/14/2024
Today
10/31/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSEAMERICAN:MTNB
CIK
N/A
Fax
N/A
Employees
32
Year Founded
N/A

Profitability

Net Income
$-22,940,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.10 million
Book Value
$4.43 per share

Miscellaneous

Free Float
4,534,000
Market Cap
$3.11 million
Optionable
Not Optionable
Beta
1.64
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

This page (NYSEAMERICAN:MTNB) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners